论文部分内容阅读
目的:探讨瑞舒伐他汀对早期糖尿病肾病(DN)患者肾脏的保护作用。方法:将62例早期DN患者随机分为两组,对照组患者给予糖尿病饮食、控制血糖和降血压等常规治疗。治疗组在常规治疗的基础上每晚给予瑞舒伐他汀10 mg,两组疗程均为4周。于治疗前和治疗4周末,检测两组尿微量白蛋白排泄率(UAER)、血肌酐(Scr)、C反应蛋白(CRP)、空腹血糖(FPG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、甘油三酯(TG)。结果:瑞舒伐他汀治疗4周后,UAER,Scr,CRP,LDL-C,TC,TG显著低于对照组(P<0.05)。结论:瑞舒伐他汀在发挥调脂作用的同时,能降低CRP及尿蛋白排泄率,延缓早期DN患者肾功能的恶化。
Objective: To investigate the protective effects of rosuvastatin on the kidney of patients with early diabetic nephropathy (DN). Methods: Sixty-two patients with early stage DN were randomly divided into two groups. Patients in the control group were given routine therapy such as diabetic diet, blood sugar control and blood pressure lowering. The treatment group was given rosuvastatin 10 mg every night on the basis of routine treatment, and the two courses of treatment were 4 weeks. The levels of urinary albumin excretion (UAER), serum creatinine (Scr), C-reactive protein (CRP), fasting blood glucose (FPG) and low density lipoprotein cholesterol (LDL- , High-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) and triglyceride (TG). Results: After 4 weeks of treatment with rosuvastatin, UAER, Scr, CRP, LDL-C, TC and TG were significantly lower than those of the control group (P <0.05). Conclusions: Rosuvastatin can decrease CRP and urinary protein excretion rate and delay the deterioration of renal function in patients with early DN while exerting lipid regulation.